I Bought a Stock Backed by David Beckham. But Not for the Reason You Think.No, it’s not because I’m a football fan. And definitely not because I think the world needs more influencer-branded supplements. I bought shares in Prenetics ($PRE) — a quirky Hong Kong-based health company — because buried inside is one of the stranger, more asymmetric setups I’ve seen in a while.Prenetics is part-genomic testing platform, part U.S. nutrition distributor, and part DTC wellness startup — now fronted by Beckham himself. It’s pivoting away from its COVID-testing past into actual consumer brands… and it might just work.It’s not a compounder. It’s a calculated flyer — the kind that could quietly 2–3x, with a floor underpinned by cash and a valuable clinical JV.The SetupEV: ~$73MNo debt and ~$48M in cashPivoting from COVID testing to consumer healthFounder-led, with meaningful insider ownership (Beckham owns 3% via DB Ventures)400%+ guided revenue growth for 2025, with strong early unit economics from IM8My base-case upside: 2–3xAt the center of it is Danny Yeung — CEO and co-founder who scaled Groupon East Asia, flipped Honey Science to PayPal. He’s got the conviction (and resume) to at least make this interesting.Either way, it’s shaping up to be a fun one to follow — and write about.What They Actually DoPrenetics made its name during the pandemic as a COVID testing provider — a business that peaked hard and then cratered just as fast. Credit to them: instead of clinging to the past, they went out and bought growth.In 2024, they acquired Europa, a major U.S. sports nutrition distributor, and launched IM8 with David Beckham. At the same time, their older business, CircleDNA, quietly doubled revenue and hit profitability. These three brands — IM8, Europa, and CircleDNA — now make up the core of Prenetics’ consumer pivot.IM8: A new premium supplement brand co-founded with David BeckhamEuropa: A U.S. sports nutrition distributor acquired in 2024 to support IM8’s growthCircleDNA: Their original direct-to-consumer genetic test, still going strongThey also still own two clinical health assets:Insighta: A JV focused on multi-cancer early detection (co-founded with Dennis Lo). Tencent recently bought 15% for $30M, implying a $200M valuation — Prenetics still holds 35%, worth ~$70M.ACT Genomics: A precision oncology business doing ~$15M in revenue — but not core anymore. Management is currently exploring a strategic review (aka looking to sell it off).Prenetics operates primarily in Hong Kong, U.S., Taiwan, and U.K. It currently has no business operations or customer data activity in mainland China.So in plain terms: they’re doubling down on the brands they own 100% and monetizing what they don’t.Why It’s Not Just HypeOkay yes, Beckham. But there’s more going on under the hood:2023 revenue (Circle DNA): $5.9M2024 (transition year - IM8 + Europa + CircleDNA) : $16.1MPrenetics released its Q1 2025 results today (ended March 31, 2025), giving us a strong early read on how the consumer pivot is performingRevenue : $14.4M vs. $3.3M in Q1 2024 → +336% YoYGross Profit: $7.3M → 52.9% marginAdjusted EBITDA Loss: $(4.8)MCash + liquid assets: $78.0M, no debtFor the full year 2025, Prenetics expects $80M–$100M in Revenue → 400+% growth and EBITDA profitable by Q4 2025IM8: Can Beckham Sell Supplements?This is Prenetics’ boldest move — a DTC supplement brand co-founded with David Beckham, backed by sleek landing pages and influencer-fueled marketing.And Beckham’s not just a face on the label. Through DB Ventures, he owns 3% of Prenetics.M8 posted some eyebrow-raising numbers:$109 average order value91% subscription rate~$64 customer acquisition cost (CAC)With a 6-month lifespan, a $109 AOV and solid CAC, Prenetics is seeing 5x+ LTV/CAC unit economics — nearly unheard of this early in a DTC launch.The big test: can these economics hold as they scale from early adopters to a broader customer base? Early signs say yes.If someone spends $106 and costs $64 to acquire, the revenue-to-CAC ratio is already solid. With 40–50% gross margins, you’re within striking distance of break-even on the first order, and profitable by the second. — and if they stick around? You’re making real money.Curious if it’s all just marketing fluff, I checked Amazon. Reviews are early but mostly legit — no obvious fake spam, people like the energy boost, and there’s praise for the packaging. Not scientific, but it feels like a real product.If IM8 can sustain that AOV and subscription rate while scaling, it could anchor the entire consumer thesis. If not, well… there’s always Beckham’s skincare line next :PValuing the Core BizCurrent Market Cap: ~$100MProjected 2025E Cash: ~$27M (based on $52M at the end of 2024 minus ~$25M in guided adjusted EBITDA losses for 2025)No DebtImplied Enterprise Value (EV): ~$73MClinical Assets (Non-Core)Insighta (35% stake)Tencent bought 15% for $30M → Implied valuation: $200MPrenetics’ 35% stake = $70MACT GenomicsI valued this at $0 — flat growth, under strategic review, and no visible momentumTotal Clinical Asset Value: $70MInsighta alone equals the entire EV. So what’s the market assigning to IM8, Europa, and CircleDNA — the actual growth engine? Basically nothing.Let’s assume they execute and hit the lower end of the revenue guidance of ~$80M, while reaching breakeven EBITDA by Q4 2025.For a triple-digit topline growth, near-profitable consumer health business with strong subscription metrics , a 3x EV/Revenue multiple is reasonable. Comparable wellness, genomics, and DTC health businesses often trade at 3–5x sales when growing at this pace.If you’ve been following me for a while, you know I care a lot about ROIC, reinvestment, and unit economics. This isn’t that. Prenetics is still unprofitable, and there's no clean way to model returns on capital yet. But in a high-growth, early-stage pivot like this, EV/Revenue is the right lens — at least until the business proves it can translate top-line into real cash flow.Sum-of-the-Parts = Significant DiscountConsumer business @ 3x revenue: $240MClinical assets: $70MTotal Value: $310MAdd back projected year-end cash: $27MFair EV: ~$337MCurrent EV = $62M → Potential upside = ~5x, assuming execution and basic market recognition of valueSanity Check?Yes, it feels wild — but the math checks out:Prenetics is guiding for 400%+ YoY revenue growthGross margins are improvingIM8 is growing >50% QoQ with a 91% subscription rateCircleDNA is already profitableBalance sheet is clean with $48M in liquidity and zero debtIf this pace holds, Prenetics’ core consumer business is massively undervalued — essentially being priced at zero despite real revenue, margin expansion, and brand traction.The story still hinges on execution — but Q1 just turned this from a speculative “maybe” into a momentum-driven “watch closely.”Execution over the next 2–3 quarters is key. But if they stay on track, a 2–3x re-rating could just be the starting line.Risks — A Trader’s Playground, Not a Sleep-Well StockLet’s be clear — this stock lives in the speculative bucket. It’s got the volatility, narrative shifts, and asymmetry that traders love. But it’s also got plenty of ways to go sideways (or straight down). Size accordingly.Here’s what could go wrong:Execution is everything. IM8’s early numbers look great, but sustaining $100+ AOV and 90%+ subscription rates at scale is a tall order. Consumer brands break more often than they break out.Europa is a mystery box. Management says Europa could break even by H2 2025 — but that still leaves a lot of open questions around margin and working capital needs.ACT could be a dead asset. Flat growth and radio silence suggest it might be worth nothing — and a strategic review doesn’t scream strength.The market may not care. U.S. investors may never value a Hong Kong-listed, microcap genomics pivot correctly. Even with execution, multiple expansion is far from guaranteed.Conclusion — Why I Bought AnywayThis isn’t a bet on multivitamins or Beckham’s brand — though that part’s fun. It’s a bet that the market’s mispricing a fast-moving pivot with real cash, real revenue, and a hidden asset greater than the whole EV.If Prenetics executes, the consumer biz alone could 2–3x the stock. If not, there’s cash and clinical assets to soften the fall.It’s a small, speculative bet — weird enough to be worth a look.I even ordered a month’s worth of IM8 strips off Amazon. If they don’t do anything for me, I’ll return the favor — and the stock.Worst case? I get to say I once co-invested with David Beckham!Disclaimer:This is not financial advice. I hold what I write about — but I’ve learned the hard way that being early and being wrong can look a lot alike. Do your own homework. All opinions are my own. I haven’t been compensated by any company to write this.Thanks for reading The 10x Radar! Subscribe for free to receive new posts and support my work.